- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05692596
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
January 24, 2024 updated by: H. Lee Moffitt Cancer Center and Research Institute
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33617
- Recruiting
- Moffitt Cancer Center
-
Sub-Investigator:
- Jason Fleming, MD, FACS
-
Sub-Investigator:
- Jason Denbo, MD
-
Contact:
- Toni Basinski
- Phone Number: 813-745-6360
- Email: Toni.Basinski@Moffitt.Org
-
Sub-Investigator:
- Mokenge Malafa, MD
-
Sub-Investigator:
- Jennifer Permuth, PhD, MS
-
Principal Investigator:
- Shaffer Mok, MD, MBS
-
Sub-Investigator:
- James R Costello, MD, PhD
-
Sub-Investigator:
- Raj Mohan Paspulati, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Patients presenting at the Moffitt GI clinic
Description
Inclusion Criteria:
- 18 years of age or older
- Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
- Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
- Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
All participants
Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.
|
Investigators will compile data typically collected clinically.
This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Database creation
Time Frame: 24 months
|
A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shaffer Mok, MD, MBS, Moffitt Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2022
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
January 11, 2023
First Submitted That Met QC Criteria
January 11, 2023
First Posted (Actual)
January 20, 2023
Study Record Updates
Last Update Posted (Actual)
January 25, 2024
Last Update Submitted That Met QC Criteria
January 24, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neurologic Manifestations
- Disease Attributes
- Disease
- Cysts
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Dyskinesias
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- DNA Repair-Deficiency Disorders
- Pancreatic Diseases
- Nevi and Melanomas
- Intestinal Polyposis
- Hyperpigmentation
- Pigmentation Disorders
- Neurocutaneous Syndromes
- Melanosis
- Cerebellar Diseases
- Primary Immunodeficiency Diseases
- Ataxia
- Spinocerebellar Ataxias
- Lentigo
- Chronic Disease
- Cerebellar Ataxia
- Nevus
- Syndrome
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Pancreatitis
- Telangiectasis
- Pancreatitis, Chronic
- Pancreatic Cyst
- Ataxia Telangiectasia
- Peutz-Jeghers Syndrome
- Dysplastic Nevus Syndrome
Other Study ID Numbers
- MCC-22156
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lynch Syndrome
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHigh-Frequency Microsatellite Instability | Mismatch Repair Gene Mutation | Mutation-Negative Lynch Syndrome | Mutation-Positive Lynch SyndromeUnited States
-
San Raffaele UniversityUnita' di Gastroenterologia - Policlinico Universitario di Bari; Unita' di... and other collaboratorsRecruitingLynch Syndrome | MLH1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | Lynch Syndrome II | Small Bowel Adenocarcinoma | Lynch Syndrome IItaly
-
Tel-Aviv Sourasky Medical CenterRambam Health Care Campus; Rabin Medical Center; Sheba Medical Center; Soroka University...Not yet recruitingLynch Syndrome I (Site-specific Colonic Cancer)Israel
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...Not yet recruitingLynch Syndrome | ContraceptionItaly
-
National Cancer Institute (NCI)RecruitingLynch SyndromeUnited States, Puerto Rico
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Imperial College LondonEnrolling by invitation
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Hospital Clinic of BarcelonaFundacion Clinic per a la Recerca BiomédicaCompleted
-
PERROD GuillaumeNot yet recruiting
Clinical Trials on Data collection
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingInfections With CPBSwitzerland
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Women and Infants Hospital of Rhode IslandTerminated
-
Centre Hospitalier Universitaire DijonCompletedCoronary Artery Bypass Graft | Anomalies in Glucose MetabolismFrance